Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTLE
5.2 PORTER
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH NEUROLOGIST
6.8 INTERVIEWS WITH ONCOLOGISTS
6.9 OTHER KOL SNAPSHOTS
7 EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATEINT TREATMENT SUCCESS RATES
8 REGULATORY & REIMBURSEMENT FRAMEWORK
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DIGITAL THERPEUTICS PIPELINE
9.3 OTHERS (PRE-CLINICAL AND RESEARCH)
10 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 BY USAGE
10.2.1 MEDICATION AUGMENTATION
10.2.2 MEDICATION REPLACEMENT
10.3 BY TYPE
10.3.1 OUTPATIENT TREATMENT
10.3.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
10.3.1.2. FLUENCY TRAINING
10.3.1.3. CONTIGENCY MANAGEMENT
10.3.1.4. CRAVING AND TRIGGER ASSESSMENT
10.3.1.5. TRANSMUCOSAL BUPRENORPHINE
10.3.1.6. OTHERS
10.3.2 MONOTHERAPY
10.3.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
10.3.2.2. COGNITIVE RESTRUCTURING
10.3.2.3. OTHERS
10.3.3 COMBINATION THERAPY
10.3.3.1. SMART WATCH
10.3.3.2. WRISTWATCH/WRISTBAND
10.3.3.3. SMART CLOTHES
10.3.3.4. EAR BANDS
10.3.3.5. OTHERS
10.3.4 OTHERS
11 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY SERVICES
11.1 OVERVIEW
11.2 PHYSICAL ACITIVITY
11.3 RELAXATION TECHNIQUE
11.4 DIET OPTIMIZATION
11.5 CONTROLLED BREATHING
11.6 TELEMEDICINE
11.7 MINDFULNESS TRAINING
11.8 OTHERS
12 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY APP ACCESSIBILITY
12.1 OVERVIEW
12.2 ANDROID
12.2.1 SMARTPHONE
12.2.2 TABLET
12.3 IOS
12.3.1 SMARTPHONE
12.3.2 TABLET
12.4 WINDOWS
12.4.1 SMARTPHONE
12.4.2 TABLET
13 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY APP TYPE
13.1 OVERVIEW
13.2 NATIVE APPS
13.3 WEB APPS
13.4 HYBRID APPS
14 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)
14.2.1 BY USAGE
14.2.1.1. MEDICATION AUGMENTATION
14.2.1.2. MEDICATION REPLACEMENT
14.2.2 BY TYPE
14.2.2.1. OUTPATIENT TREATMENT
14.2.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
14.2.2.1.2. FLUENCY TRAINING
14.2.2.1.3. CONTIGENCY MANAGEMENT
14.2.2.1.4. CRAVING AND TRIGGER ASSESSMENT
14.2.2.1.5. TRANSMUCOSAL BUPRENORPHINE
14.2.2.1.6. OTHERS
14.2.2.2. MONOTHERAPY
14.2.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
14.2.2.2.2. COGNITIVE RESTRUCTURING
14.2.2.2.3. OTHERS
14.2.2.3. COMBINATION THERAPY
14.2.2.3.1. SMART WATCH
14.2.2.3.2. WRISTWATCH/WRISTBAND
14.2.2.3.3. SMART CLOTHES
14.2.2.3.4. EAR BANDS
14.2.2.3.5. OTHERS
14.3 ALZHEIMER’S DISEASE
14.3.1 BY USAGE
14.3.1.1. MEDICATION AUGMENTATION
14.3.1.2. MEDICATION REPLACEMENT
14.3.2 BY TYPE
14.3.2.1. OUTPATIENT TREATMENT
14.3.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
14.3.2.1.2. FLUENCY TRAINING
14.3.2.1.3. CONTIGENCY MANAGEMENT
14.3.2.1.4. CRAVING AND TRIGGER ASSESSMENT
14.3.2.1.5. TRANSMUCOSAL BUPRENORPHINE
14.3.2.1.6. OTHERS
14.3.2.2. MONOTHERAPY
14.3.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
14.3.2.2.2. COGNITIVE RESTRUCTURING
14.3.2.2.3. OTHERS
14.3.2.3. COMBINATION THERAPY
14.3.2.3.1. SMART WATCH
14.3.2.3.2. WRISTWATCH/WRISTBAND
14.3.2.3.3. SMART CLOTHES
14.3.2.3.4. EAR BANDS
14.3.2.3.5. OTHERS
14.3.2.4. OTHERS
14.4 MAJOR DEPRESSIVE DISORDER (MDD)
14.4.1 BY USAGE
14.4.1.1. MEDICATION AUGMENTATION
14.4.1.2. MEDICATION REPLACEMENT
14.4.2 BY TYPE
14.4.2.1. OUTPATIENT TREATMENT
14.4.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
14.4.2.1.2. FLUENCY TRAINING
14.4.2.1.3. CONTIGENCY MANAGEMENT
14.4.2.1.4. CRAVING AND TRIGGER ASSESSMENT
14.4.2.1.5. TRANSMUCOSAL BUPRENORPHINE
14.4.2.1.6. OTHERS
14.4.2.2. MONOTHERAPY
14.4.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
14.4.2.2.2. COGNITIVE RESTRUCTURING
14.4.2.2.3. OTHERS
14.4.2.3. COMBINATION THERAPY
14.4.2.3.1. SMART WATCH
14.4.2.3.2. WRISTWATCH/WRISTBAND
14.4.2.3.3. SMART CLOTHES
14.4.2.3.4. EAR BANDS
14.4.2.3.5. OTHERS
14.4.2.4. OTHERS
14.5 INSOMNIA
14.5.1 BY USAGE
14.5.1.1. MEDICATION AUGMENTATION
14.5.1.2. MEDICATION REPLACEMENT
14.5.2 BY TYPE
14.5.2.1. OUTPATIENT TREATMENT
14.5.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
14.5.2.1.2. FLUENCY TRAINING
14.5.2.1.3. CONTIGENCY MANAGEMENT
14.5.2.1.4. CRAVING AND TRIGGER ASSESSMENT
14.5.2.1.5. TRANSMUCOSAL BUPRENORPHINE
14.5.2.1.6. OTHERS
14.5.2.2. MONOTHERAPY
14.5.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
14.5.2.2.2. COGNITIVE RESTRUCTURING
14.5.2.2.3. OTHERS
14.5.2.3. COMBINATION THERAPY
14.5.2.3.1. SMART WATCH
14.5.2.3.2. WRISTWATCH/WRISTBAND
14.5.2.3.3. SMART CLOTHES
14.5.2.3.4. EAR BANDS
14.5.2.3.5. OTHERS
14.5.2.4. OTHERS
14.6 COGNITION
14.6.1 BY USAGE
14.6.1.1. MEDICATION AUGMENTATION
14.6.1.2. MEDICATION REPLACEMENT
14.6.2 BY TYPE
14.6.2.1. OUTPATIENT TREATMENT
14.6.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
14.6.2.1.2. FLUENCY TRAINING
14.6.2.1.3. CONTIGENCY MANAGEMENT
14.6.2.1.4. CRAVING AND TRIGGER ASSESSMENT
14.6.2.1.5. TRANSMUCOSAL BUPRENORPHINE
14.6.2.1.6. OTHERS
14.6.2.2. MONOTHERAPY
14.6.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
14.6.2.2.2. COGNITIVE RESTRUCTURING
14.6.2.2.3. OTHERS
14.6.2.3. COMBINATION THERAPY
14.6.2.3.1. SMART WATCH
14.6.2.3.2. WRISTWATCH/WRISTBAND
14.6.2.3.3. SMART CLOTHES
14.6.2.3.4. EAR BANDS
14.6.2.3.5. OTHERS
14.6.2.4. OTHERS
14.7 EPILEPSY
14.7.1 BY USAGE
14.7.1.1. MEDICATION AUGMENTATION
14.7.1.2. MEDICATION REPLACEMENT
14.7.2 BY TYPE
14.7.2.1. OUTPATIENT TREATMENT
14.7.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
14.7.2.1.2. FLUENCY TRAINING
14.7.2.1.3. CONTIGENCY MANAGEMENT
14.7.2.1.4. CRAVING AND TRIGGER ASSESSMENT
14.7.2.1.5. TRANSMUCOSAL BUPRENORPHINE
14.7.2.1.6. OTHERS
14.7.2.2. MONOTHERAPY
14.7.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
14.7.2.2.2. COGNITIVE RESTRUCTURING
14.7.2.2.3. OTHERS
14.7.2.3. COMBINATION THERAPY
14.7.2.3.1. SMART WATCH
14.7.2.3.2. WRISTWATCH/WRISTBAND
14.7.2.3.3. SMART CLOTHES
14.7.2.3.4. EAR BANDS
14.7.2.3.5. OTHERS
14.7.2.4. OTHERS
14.8 MOVEMENT DISORDER
14.8.1 BY USAGE
14.8.1.1. MEDICATION AUGMENTATION
14.8.1.2. MEDICATION REPLACEMENT
14.8.2 BY TYPE
14.8.2.1. OUTPATIENT TREATMENT
14.8.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
14.8.2.1.2. FLUENCY TRAINING
14.8.2.1.3. CONTIGENCY MANAGEMENT
14.8.2.1.4. CRAVING AND TRIGGER ASSESSMENT
14.8.2.1.5. TRANSMUCOSAL BUPRENORPHINE
14.8.2.1.6. OTHERS
14.8.2.2. MONOTHERAPY
14.8.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
14.8.2.2.2. COGNITIVE RESTRUCTURING
14.8.2.2.3. OTHERS
14.8.2.3. COMBINATION THERAPY
14.8.2.3.1. SMART WATCH
14.8.2.3.2. WRISTWATCH/WRISTBAND
14.8.2.3.3. SMART CLOTHES
14.8.2.3.4. EAR BANDS
14.8.2.3.5. OTHERS
14.8.2.4. OTHERS
14.9 AUSTISM SPECTRUM DISORDER
14.9.1 BY USAGE
14.9.1.1. MEDICATION AUGMENTATION
14.9.1.2. MEDICATION REPLACEMENT
14.9.2 BY TYPE
14.9.2.1. OUTPATIENT TREATMENT
14.9.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
14.9.2.1.2. FLUENCY TRAINING
14.9.2.1.3. CONTIGENCY MANAGEMENT
14.9.2.1.4. CRAVING AND TRIGGER ASSESSMENT
14.9.2.1.5. TRANSMUCOSAL BUPRENORPHINE
14.9.2.1.6. OTHERS
14.9.2.2. MONOTHERAPY
14.9.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
14.9.2.2.2. COGNITIVE RESTRUCTURING
14.9.2.2.3. OTHERS
14.9.2.3. COMBINATION THERAPY
14.9.2.3.1. SMART WATCH
14.9.2.3.2. WRISTWATCH/WRISTBAND
14.9.2.3.3. SMART CLOTHES
14.9.2.3.4. EAR BANDS
14.9.2.3.5. OTHERS
14.9.2.4. OTHERS
14.1 ONCOLOGY
14.10.1 BY USAGE
14.10.1.1. MEDICATION AUGMENTATION
14.10.1.2. MEDICATION REPLACEMENT
14.10.2 BY TYPE
14.10.2.1. OUTPATIENT TREATMENT
14.10.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
14.10.2.1.2. FLUENCY TRAINING
14.10.2.1.3. CONTIGENCY MANAGEMENT
14.10.2.1.4. CRAVING AND TRIGGER ASSESSMENT
14.10.2.1.5. TRANSMUCOSAL BUPRENORPHINE
14.10.2.1.6. OTHERS
14.10.2.2. MONOTHERAPY
14.10.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
14.10.2.2.2. COGNITIVE RESTRUCTURING
14.10.2.2.3. OTHERS
14.10.2.3. COMBINATION THERAPY
14.10.2.3.1. SMART WATCH
14.10.2.3.2. WRISTWATCH/WRISTBAND
14.10.2.3.3. SMART CLOTHES
14.10.2.3.4. EAR BANDS
14.10.2.3.5. OTHERS
14.10.2.4. OTHERS
15 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY PATIENTS
15.1 OVERVIEW
15.2 CHILDREN
15.3 ADULTS
15.4 GERIATRICS
16 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16.2 COMPANY SHARE ANALYSIS: EUROPE
16.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16.4 MERGERS & ACQUISITIONS
16.5 NEW PRODUCT DEVELOPMENT & APPROVALS
16.6 EXPANSIONS
16.7 REGULATORY CHANGES
16.8 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
17 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY GEOGRAPHY
17.1 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
17.1.1 NORTH AMERICA
17.1.1.1. U.S.
17.1.1.2. CANADA
17.1.1.3. MEXICO
17.1.2 EUROPE
17.1.2.1. GERMANY
17.1.2.2. FRANCE
17.1.2.3. U.K.
17.1.2.4. HUNGARY
17.1.2.5. LITHUANIA
17.1.2.6. AUSTRIA
17.1.2.7. IRELAND
17.1.2.8. NORWAY
17.1.2.9. POLAND
17.1.2.10. ITALY
17.1.2.11. SPAIN
17.1.2.12. RUSSIA
17.1.2.13. TURKEY
17.1.2.14. NETHERLANDS
17.1.2.15. SWITZERLAND
17.1.2.16. REST OF EUROPE
17.1.3 ASIA-PACIFIC
17.1.3.1. JAPAN
17.1.3.2. CHINA
17.1.3.3. SOUTH KOREA
17.1.3.4. INDIA
17.1.3.5. AUSTRALIA
17.1.3.6. SINGAPORE
17.1.3.7. THAILAND
17.1.3.8. MALAYSIA
17.1.3.9. INDONESIA
17.1.3.10. PHILIPPINES
17.1.3.11. VIETNAM
17.1.3.12. REST OF ASIA-PACIFIC
17.1.4 SOUTH AMERICA
17.1.4.1. BRAZIL
17.1.4.2. ARGENTINA
17.1.4.3. PERU
17.1.4.4. REST OF SOUTH AMERICA
17.1.5 MIDDLE EAST AND AFRICA
17.1.5.1. SOUTH AFRICA
17.1.5.2. SAUDI ARABIA
17.1.5.3. UAE
17.1.5.4. EGYPT
17.1.5.5. KUWAIT
17.1.5.6. ISRAEL
17.1.5.7. REST OF MIDDLE EAST AND AFRICA
17.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
18 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, SWOT AND DBMR ANALYSIS
19 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, COMPANY PROFILE
19.1 PEAR THERAPEUTICS, INC.
19.1.1 COMPANY OVERVIEW
19.1.2 REVENUE ANALYSIS
19.1.3 GEOGRAPHIC PRESENCE
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPEMENTS
19.2 AKILI INTERACTIVE LABS, INC.
19.2.1 COMPANY OVERVIEW
19.2.2 REVENUE ANALYSIS
19.2.3 GEOGRAPHIC PRESENCE
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPEMENTS
19.3 CLICK THERAPEUTICS, INC.
19.3.1 COMPANY OVERVIEW
19.3.2 REVENUE ANALYSIS
19.3.3 GEOGRAPHIC PRESENCE
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPEMENTS
19.4 BETTER THERAPEUTICS, LLC
19.4.1 COMPANY OVERVIEW
19.4.2 REVENUE ANALYSIS
19.4.3 GEOGRAPHIC PRESENCE
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPEMENTS
19.5 XEALTH
19.5.1 COMPANY OVERVIEW
19.5.2 REVENUE ANALYSIS
19.5.3 GEOGRAPHIC PRESENCE
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPEMENTS
19.6 KAIA HEALTH
19.6.1 COMPANY OVERVIEW
19.6.2 REVENUE ANALYSIS
19.6.3 GEOGRAPHIC PRESENCE
19.6.4 PRODUCT PORTFOLIO
19.6.5 RECENT DEVELOPEMENTS
19.7 OMADA HEALTH, INC.
19.7.1 COMPANY OVERVIEW
19.7.2 REVENUE ANALYSIS
19.7.3 GEOGRAPHIC PRESENCE
19.7.4 PRODUCT PORTFOLIO
19.7.5 RECENT DEVELOPEMENTS
19.8 WELLDOC
19.8.1 COMPANY OVERVIEW
19.8.2 REVENUE ANALYSIS
19.8.3 GEOGRAPHIC PRESENCE
19.8.4 PRODUCT PORTFOLIO
19.8.5 RECENT DEVELOPEMENTS
19.9 VOLUNTIS
19.9.1 COMPANY OVERVIEW
19.9.2 REVENUE ANALYSIS
19.9.3 GEOGRAPHIC PRESENCE
19.9.4 PRODUCT PORTFOLIO
19.9.5 RECENT DEVELOPEMENTS
19.1 SOLERA NETWORK
19.10.1 COMPANY OVERVIEW
19.10.2 REVENUE ANALYSIS
19.10.3 GEOGRAPHIC PRESENCE
19.10.4 PRODUCT PORTFOLIO
19.10.5 RECENT DEVELOPEMENTS
19.11 2MORROW INC.
19.11.1 COMPANY OVERVIEW
19.11.2 REVENUE ANALYSIS
19.11.3 GEOGRAPHIC PRESENCE
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPEMENTS
19.12 GAIA
19.12.1 COMPANY OVERVIEW
19.12.2 REVENUE ANALYSIS
19.12.3 GEOGRAPHIC PRESENCE
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPEMENTS
19.13 RESMED
19.13.1 COMPANY OVERVIEW
19.13.2 REVENUE ANALYSIS
19.13.3 GEOGRAPHIC PRESENCE
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPEMENTS
19.14 DTHERA SCIENCES
19.14.1 COMPANY OVERVIEW
19.14.2 REVENUE ANALYSIS
19.14.3 GEOGRAPHIC PRESENCE
19.14.4 PRODUCT PORTFOLIO
19.14.5 RECENT DEVELOPEMENTS
19.15 SAMSUNG
19.15.1 COMPANY OVERVIEW
19.15.2 REVENUE ANALYSIS
19.15.3 GEOGRAPHIC PRESENCE
19.15.4 PRODUCT PORTFOLIO
19.15.5 RECENT DEVELOPEMENTS
19.16 BIGHEALTH
19.16.1 COMPANY OVERVIEW
19.16.2 REVENUE ANALYSIS
19.16.3 GEOGRAPHIC PRESENCE
19.16.4 PRODUCT PORTFOLIO
19.16.5 RECENT DEVELOPEMENTS
19.17 PROPELLER HEALTH
19.17.1 COMPANY OVERVIEW
19.17.2 REVENUE ANALYSIS
19.17.3 GEOGRAPHIC PRESENCE
19.17.4 PRODUCT PORTFOLIO
19.17.5 RECENT DEVELOPEMENTS
19.18 F. HOFFMANN-LA ROCHE LTD
19.18.1 COMPANY OVERVIEW
19.18.2 REVENUE ANALYSIS
19.18.3 GEOGRAPHIC PRESENCE
19.18.4 PRODUCT PORTFOLIO
19.18.5 RECENT DEVELOPEMENTS
19.19 LIMBIX HEALTH, INC
19.19.1 COMPANY OVERVIEW
19.19.2 REVENUE ANALYSIS
19.19.3 GEOGRAPHIC PRESENCE
19.19.4 PRODUCT PORTFOLIO
19.19.5 RECENT DEVELOPEMENTS
19.2 NUVOAIR AB
19.20.1 COMPANY OVERVIEW
19.20.2 REVENUE ANALYSIS
19.20.3 GEOGRAPHIC PRESENCE
19.20.4 PRODUCT PORTFOLIO
19.20.5 RECENT DEVELOPEMENTS
19.21 ALTRAN
19.21.1 COMPANY OVERVIEW
19.21.2 REVENUE ANALYSIS
19.21.3 GEOGRAPHIC PRESENCE
19.21.4 PRODUCT PORTFOLIO
19.21.5 RECENT DEVELOPEMENTS
19.22 SENSYNE HEALTH PLC
19.22.1 COMPANY OVERVIEW
19.22.2 REVENUE ANALYSIS
19.22.3 GEOGRAPHIC PRESENCE
19.22.4 PRODUCT PORTFOLIO
19.22.5 RECENT DEVELOPEMENTS
19.23 BIOFOURMIS
19.23.1 COMPANY OVERVIEW
19.23.2 REVENUE ANALYSIS
19.23.3 GEOGRAPHIC PRESENCE
19.23.4 PRODUCT PORTFOLIO
19.23.5 RECENT DEVELOPEMENTS
19.24 SMARTPATIENT GMBH
19.24.1 COMPANY OVERVIEW
19.24.2 REVENUE ANALYSIS
19.24.3 GEOGRAPHIC PRESENCE
19.24.4 PRODUCT PORTFOLIO
19.24.5 RECENT DEVELOPMENTS
19.25 BOEHRINGER INGELHEIM
19.25.1 COMPANY OVERVIEW
19.25.2 REVENUE ANALYSIS
19.25.3 GEOGRAPHIC PRESENCE
19.25.4 PRODUCT PORTFOLIO
19.25.5 RECENT DEVELOPMENTS
19.26 BIG HEALTH
19.26.1 COMPANY OVERVIEW
19.26.2 REVENUE ANALYSIS
19.26.3 GEOGRAPHIC PRESENCE
19.26.4 PRODUCT PORTFOLIO
19.26.5 RECENT DEVELOPMENTS
19.27 COGNOA
19.27.1 COMPANY OVERVIEW
19.27.2 REVENUE ANALYSIS
19.27.3 GEOGRAPHIC PRESENCE
19.27.4 PRODUCT PORTFOLIO
19.27.5 RECENT DEVELOPMENTS
19.28 GLOOKO
19.28.1 COMPANY OVERVIEW
19.28.2 REVENUE ANALYSIS
19.28.3 GEOGRAPHIC PRESENCE
19.28.4 PRODUCT PORTFOLIO
19.28.5 RECENT DEVELOPMENTS
19.29 WELLDOC
19.29.1 COMPANY OVERVIEW
19.29.2 REVENUE ANALYSIS
19.29.3 GEOGRAPHIC PRESENCE
19.29.4 PRODUCT PORTFOLIO
19.29.5 RECENT DEVELOPMENTS
19.3 MEDRHYTHMS
19.30.1 COMPANY OVERVIEW
19.30.2 REVENUE ANALYSIS
19.30.3 GEOGRAPHIC PRESENCE
19.30.4 PRODUCT PORTFOLIO
19.30.5 RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
20 RELATED REPORTS
21 CONCLUSION
22 QUESTIONNAIRE
23 ABOUT DATA BRIDGE MARKET RESEARCH
